…
Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye diseases, including slit lamps, refractometers, and tonometers; optical coherence tomography and fundus cameras for retina examination; functional glaucoma diagnostic devices (perimeters); surgical ophthalmology products comprising surgical microscopes, biometers, and phacoemulsification and vitrectomy equipment; intraocular lenses for cataract surgery; and systems and consumables for laser eye surgery that include the VISUMAX femtosecond laser, which enables minimally invasive correction of vision defects using lenticular extraction, as well as digital products for the storage, analysis, and sharing of clinical data. The Microsurgery segment provides products and solutions for minimally invasive surgical treatments, including surgical visualization, interoperative radiotherapy, interoperative pathology, special surgical instruments, and digital solutions, as well as the ZEISS Tumor Workflow, a cross-product workflow solution. It serves physicians in various fields and hospitals. The company was founded in 1846 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG operates as a subsidiary of ZEISS Group.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Carl Zeiss Meditec AG makes ophthalmic diagnostic and surgical systems, including imaging, microscopes and consumables. Long-term growth could be driven by aging populations, rising cataract and refractive procedures, geographic expansion and product innovation that supports recurring aftermarket sales. The company's established brand and installed base may provide steady revenue streams.
Key risks include sensitivity to procedure volumes and reimbursement, regulatory approvals, competitive and execution risks, plus supply-chain and currency exposure.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
| Income before tax | 193.89M | 240.87M | 412.56M | 403.49M | 339.05M |
| Minority interest | -1.14M | -1.43M | -1.61M | -2.00M | -1.24M |
| Net income | 141.21M | 178.73M | 290.40M | 293.91M | 236.28M |
| Selling general administrative | 131.42M | 111.01M | 83.78M | 77.88M | 60.75M |
| Selling and marketing expenses | 495.10M | 458.20M | 420.28M | 360.18M | 303.23M |
| Gross profit | 1175.20M | 1088.63M | 1205.77M | 1127.60M | 967.21M |
| Reconciled depreciation | 126.38M | 132.77M | 74.06M | 69.77M | 61.58M |
| Ebit | 220.52M | 187.41M | 427.81M | 413.08M | 348.42M |
| Ebitda | 346.89M | 225.05M | 501.88M | 482.85M | 410.00M |
| Depreciation and amortization | 126.38M | 37.64M | 74.06M | 69.77M | 61.58M |
| Operating income | 223.32M | 121.35M | 427.81M | 413.08M | 348.42M |
| Other operating expenses | 2004.33M | 1944.78M | 1741.18M | 1505.96M | 1273.17M |
| Interest expense | 29.37M | 31.89M | 15.25M | 9.59M | 9.37M |
| Tax provision | 51.55M | 60.71M | 120.56M | 107.58M | 101.53M |
| Interest income | 6.57M | 23.27M | 29.05M | 13.25M | 1.56M |
| Net interest income | -19.00M | 37.85M | 27.13M | 55.24M | -9.46M |
| Income tax expense | 48.59M | 60.71M | 120.56M | 107.58M | 101.53M |
| Total revenue | 2227.64M | 2066.13M | 2089.30M | 1902.84M | 1646.79M |
| Total operating expenses | 951.88M | 967.28M | 857.64M | 730.72M | 593.60M |
| Cost of revenue | 1052.45M | 977.50M | 883.53M | 775.24M | 679.57M |
| Total other income expense net | -29.43M | 119.52M | -15.25M | -9.59M | -9.37M |
| Net income from continuing ops | 142.34M | 180.15M | 292.01M | 295.91M | 237.52M |
| Net income applicable to common shares | - | - | - | 293.91M | 236.28M |
| Breakdown | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
| Total assets | 4064.84M | 3393.20M | 3032.92M | 2822.82M | 2395.97M |
| Intangible assets | 778.88M | 706.85M | 259.49M | 240.43M | 153.70M |
| Other current assets | 167.37M | 72.85M | - | 23.66M | 1310.20M |
| Total liab | 1564.79M | 1336.72M | 860.02M | 792.73M | 718.59M |
| Total stockholder equity | 2486.89M | 2041.70M | 2159.45M | 2015.10M | 1659.33M |
| Deferred long term liab | - | - | - | 224.83M | 137.12M |
| Other current liab | 318.86M | 324.88M | 300.04M | 328.54M | 2.89M |
| Common stock | 105.09M | 89.44M | 89.44M | 89.44M | 89.44M |
| Capital stock | 89.44M | 89.44M | 89.44M | 89.44M | 89.44M |
| Retained earnings | 1850.76M | 1486.42M | 1405.90M | 1213.89M | 1000.48M |
| Other liab | - | - | - | 147.09M | 168.54M |
| Good will | 1139.44M | 982.50M | 415.78M | 429.65M | 328.71M |
| Other assets | - | - | - | 373.59M | 262.56M |
| Cash | 27.27M | 20.29M | 10.60M | 7.73M | 7.44M |
| Total current liabilities | 543.81M | 568.84M | 561.65M | 539.32M | 448.12M |
| Current deferred revenue | - | - | 294.47M | - | 280.43M |
| Net debt | 105.19M | 133.54M | 145.09M | 120.17M | 113.83M |
| Short term debt | 67.97M | 27.07M | 21.82M | 21.59M | 19.34M |
| Short long term debt total | 132.46M | 153.83M | 155.70M | 127.90M | 121.27M |
| Other stockholder equity | 552.32M | 470.06M | 664.11M | 711.77M | 569.41M |
| Property plant equipment | - | - | - | 201.30M | 177.39M |
| Total current assets | 1504.35M | 1212.48M | 1911.73M | 1791.85M | 1604.02M |
| Net tangible assets | - | - | - | 1569.86M | 1314.04M |
| Short term investments | - | - | - | - | -17.52M |
| Net receivables | 812.73M | 583.18M | 196.92M | 1365.27M | 1293.70M |
| Inventory | 496.98M | 536.16M | 520.23M | 382.75M | 286.38M |
| Accounts payable | 127.99M | 183.54M | 239.79M | 189.19M | 145.47M |
| Accumulated other comprehensive income | -21.28M | -4.23M | - | - | - |
| Non currrent assets other | 159.98M | 30.90M | 66.45M | 52.99M | 0.79M |
| Non current assets total | 2560.49M | 2180.72M | 1121.20M | 1030.96M | 791.95M |
| Capital lease obligations | 132.46M | 151.35M | 155.70M | 127.90M | 121.27M |
| Breakdown | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
| Investments | -25.65M | -412.31M | -110.98M | -67.14M | -13.93M |
| Change to liabilities | - | - | - | 33.73M | 52.69M |
| Total cashflows from investing activities | -100.49M | -412.31M | - | -148.89M | -75.20M |
| Net borrowings | 0.07M | 400.21M | - | -21.96M | -17.31M |
| Total cash from financing activities | -120.14M | 176.25M | -135.09M | -38.24M | -285.89M |
| Change to operating activities | - | - | - | 5.76M | 61.04M |
| Net income | 142.34M | 180.15M | 292.01M | 295.91M | 237.52M |
| Change in cash | 9.40M | 9.68M | 2.87M | 0.29M | 1.24M |
| Begin period cash flow | 22.64M | 10.60M | 7.73M | 7.44M | 6.20M |
| End period cash flow | 32.04M | 20.29M | 10.60M | 7.73M | 7.44M |
| Total cash from operating activities | 231.68M | 247.32M | 250.86M | 188.20M | 362.66M |
| Depreciation | 126.38M | 132.77M | 74.06M | 69.77M | 61.58M |
| Other cashflows from investing activities | -32.98M | -65.32M | - | - | - |
| Dividends paid | 57.98M | 98.20M | 98.39M | 80.50M | 44.72M |
| Change to inventory | 26.60M | 24.38M | -152.60M | -74.63M | 0.02M |
| Change to account receivables | -106.48M | 21.62M | - | -74.37M | -62.10M |
| Sale purchase of stock | 0.00M | -150.07M | - | - | - |
| Other cashflows from financing activities | -62.24M | 24.32M | -36.71M | 42.26M | -241.17M |
| Change to netincome | - | - | - | -65.97M | 13.16M |
| Capital expenditures | 43.49M | 152.20M | 113.86M | 81.97M | 66.10M |
| Change in working capital | -36.67M | 15.10M | -125.88M | -109.51M | 51.65M |
| Other non cash items | -0.38M | -80.71M | 10.67M | -67.97M | 11.91M |
| Free cash flow | 188.19M | 95.11M | 137.00M | 106.23M | 296.56M |
Sector: Healthcare Industry: Medical Instruments & Supplies
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CZMWY Carl Zeiss Meditec AG ADR |
-0.77 2.17% |
34.65 | 17.37 | 19.19 | 1.30 | 1.15 | 1.14 | 7.35 |
| ISRG Intuitive Surgical Inc |
-8.32 2.04% |
398.92 | 43.30 | 31.35 | 12.25 | 7.35 | 11.63 | 30.22 |
| ESLOF EssilorLuxottica Société anonyme |
-2.84 1.45% |
192.96 | 44.84 | 27.62 | 4.07 | 2.49 | 3.71 | 16.04 |
| ESLOY Essilor International SA |
-1.82 1.88% |
95.04 | 41.68 | 27.25 | 3.94 | 2.45 | 3.71 | 16.04 |
| BDX Becton Dickinson and Company |
0.10 0.05% |
212.78 | 31.62 | 13.76 | 2.25 | 2.04 | 2.93 | 13.40 |
Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye diseases, including slit lamps, refractometers, and tonometers; optical coherence tomography and fundus cameras for retina examination; functional glaucoma diagnostic devices (perimeters); surgical ophthalmology products comprising surgical microscopes, biometers, and phacoemulsification and vitrectomy equipment; intraocular lenses for cataract surgery; and systems and consumables for laser eye surgery that include the VISUMAX femtosecond laser, which enables minimally invasive correction of vision defects using lenticular extraction, as well as digital products for the storage, analysis, and sharing of clinical data. The Microsurgery segment provides products and solutions for minimally invasive surgical treatments, including surgical visualization, interoperative radiotherapy, interoperative pathology, special surgical instruments, and digital solutions, as well as the ZEISS Tumor Workflow, a cross-product workflow solution. It serves physicians in various fields and hospitals. The company was founded in 1846 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG operates as a subsidiary of ZEISS Group.
Göschwitzer Straße 51-52, Jena, Germany, 07745
49 3641 220 115
5784
| Name | Title | Year Born |
|---|---|---|
| Mr. Justus Felix Wehmer | CFO & Member of the Management Board | 1965 |
| Dr. Markus Weber | Pres, CEO & Chairman of Management Board | NA |
| Mr. Sebastian Frericks | Director of Investor Relations | NA |
| Mr. Martin Wiechmann | Head of the Planetarium Bus. Unit | NA |
| Mr. Mike Wang | Head of Marketing - Shanghai | NA |
| Mr. Steven C. Schallhorn M.D. | Chief Medical Officer for Global Ophthalmic Devices | NA |
| Mr. Andrew Chang | Head of Sales for Ophthalmic Devices & Pres of Carl Zeiss Meditec, Inc. | NA |
| Laurie Ferguson | Head of Global Communications Ophthalmic Devices | NA |
| Dr. Euan S. Thomson Ph.D. | Pres of Ophthalmic Devices & Head of the Ophthalmic Devices Strategic Bus. Unit | 1963 |
| Dr. Christian Munster | Head of Global Regulatory & Clinical Affairs, CoCe Site Jena & Emp. Rep. Member of Supervisory Board | 1971 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.